Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01728792 · ClinicalTrials.gov registry record · Phase 1
Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT01728792 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 80 participants.
The verdict
NCT01728792, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study assessed the safety and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) previously referred to as DENVax of various dosing schedules via subcutaneous (SC) or intramuscular (IM) administration with needle/syringe or needle-free injector (PharmaJet Stratis™).
Interventions
- BIOLOGICAL TDV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2013-01-22 |
| Est. Completion | 2013-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01728792
The ClinicalTrials.gov registry entry for NCT01728792 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TDV is the first listed.
NCT01728792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01728792 about?
NCT01728792 is a clinical study titled "Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity". This study assessed the safety and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) previously referred to as DENVax of various dosing schedules via subcutaneous (SC) or intramuscular (IM) administration with needle/syringe or needle-free injector (PharmaJet Stratis™).
What is the current status of trial NCT01728792?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2013-01-22. Estimated completion is 2013-11-21.
What interventions are being tested in trial NCT01728792?
The interventions under investigation include: TDV (BIOLOGICAL).
Who is sponsoring clinical trial NCT01728792?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.